PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28859672-8	2017	Laquinimod-treated patients showed more abnormal laboratory levels in liver enzymes, P-amylase, C-reactive protein (CRP), and fibrinogen, but most shifts were clinically non-significant.	laquinimod	0-10	C-reactive protein	Homo sapiens	96-114
29304807-10	2018	Concomitantly, laquinimod significantly increased the levels of the glial glutamate transporter 1 (GLT-1) protein and pharmacological blockade of GLT-1 function fully abolished laquinimod anti-excitotoxic effect.	laquinimod	15-25	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	74-95
29304807-10	2018	Concomitantly, laquinimod significantly increased the levels of the glial glutamate transporter 1 (GLT-1) protein and pharmacological blockade of GLT-1 function fully abolished laquinimod anti-excitotoxic effect.	laquinimod	15-25	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	99-104
29304807-10	2018	Concomitantly, laquinimod significantly increased the levels of the glial glutamate transporter 1 (GLT-1) protein and pharmacological blockade of GLT-1 function fully abolished laquinimod anti-excitotoxic effect.	laquinimod	177-187	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	99-104
29304807-10	2018	Concomitantly, laquinimod significantly increased the levels of the glial glutamate transporter 1 (GLT-1) protein and pharmacological blockade of GLT-1 function fully abolished laquinimod anti-excitotoxic effect.	laquinimod	177-187	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	146-151
28859672-8	2017	Laquinimod-treated patients showed more abnormal laboratory levels in liver enzymes, P-amylase, C-reactive protein (CRP), and fibrinogen, but most shifts were clinically non-significant.	laquinimod	0-10	C-reactive protein	Homo sapiens	116-119
28243182-9	2017	Laquinimod was also associated with asymptomatic changes in liver enzyme levels, fibrinogen levels, and hematologic parameters that followed a consistent temporal pattern: mild, nonprogressive, and occurring within 90 days of treatment initiation, then stabilizing or reverting to baseline levels during continued treatment.	laquinimod	0-10	fibrinogen beta chain	Homo sapiens	81-91
28433708-4	2017	They represent, as diacetyl prodrugs, AHR-active metabolites of the drug compounds laquinimod and tasquinimod, respectively, which are intended for the treatment of autoimmune diseases and cancer.	laquinimod	83-93	aryl hydrocarbon receptor	Rattus norvegicus	38-41
27671624-0	2016	Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor.	laquinimod	0-10	aryl-hydrocarbon receptor	Mus musculus	79-104
27671624-3	2016	Analysis of genome-wide expression data revealed activation of the aryl hydrocarbon receptor (AhR) pathway in laquinimod-treated mice.	laquinimod	110-120	aryl-hydrocarbon receptor	Mus musculus	67-92
27671624-3	2016	Analysis of genome-wide expression data revealed activation of the aryl hydrocarbon receptor (AhR) pathway in laquinimod-treated mice.	laquinimod	110-120	aryl-hydrocarbon receptor	Mus musculus	94-97
27671624-6	2016	We demonstrate that the pronounced effect of laquinimod on clinical score, CNS inflammation, and demyelination in EAE was abolished in AhR-/- mice.	laquinimod	45-55	aryl-hydrocarbon receptor	Mus musculus	135-138
27671624-8	2016	These data strongly support the idea that AhR is necessary for the efficacy of laquinimod in EAE and that laquinimod may represent a first-in-class drug targeting AhR for the treatment of multiple sclerosis and other neurodegenerative diseases.	laquinimod	79-89	aryl-hydrocarbon receptor	Mus musculus	42-45
27671624-8	2016	These data strongly support the idea that AhR is necessary for the efficacy of laquinimod in EAE and that laquinimod may represent a first-in-class drug targeting AhR for the treatment of multiple sclerosis and other neurodegenerative diseases.	laquinimod	106-116	aryl-hydrocarbon receptor	Mus musculus	163-166
27704036-9	2016	Treatment of spontaneous EAE with laquinimod was also associated with increases in CD4+CD25hiFoxp3+ and CD4+CD25+IL-10+ regulatory T cells.	laquinimod	34-44	interleukin 2 receptor, alpha chain	Mus musculus	87-91
27695399-8	2016	Lastly, we will review four new MS treatments which interrupt NF-kappaB pathways-fingolimod, teriflunomide, dimethyl fumarate (DMF) and laquinimod (LAQ)-and explain their mechanisms, and the possible strategy for MS treatments in the future.	laquinimod	136-146	nuclear factor kappa B subunit 1	Homo sapiens	62-71
27695399-8	2016	Lastly, we will review four new MS treatments which interrupt NF-kappaB pathways-fingolimod, teriflunomide, dimethyl fumarate (DMF) and laquinimod (LAQ)-and explain their mechanisms, and the possible strategy for MS treatments in the future.	laquinimod	148-151	nuclear factor kappa B subunit 1	Homo sapiens	62-71
27296315-0	2016	Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons.	laquinimod	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	21-24
27296315-0	2016	Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons.	laquinimod	0-10	caspase 6	Homo sapiens	48-57
27296315-7	2016	We find that laquinimod ameliorates DNA-damage induced activation of caspase-6 in primary neuronal cultures.	laquinimod	13-23	caspase 6	Homo sapiens	69-78
27609269-0	2016	The immunomodulatory effect of laquinimod in CNS autoimmunity is mediated by the aryl hydrocarbon receptor.	laquinimod	31-41	aryl-hydrocarbon receptor	Mus musculus	81-106
27609269-4	2016	Thus, our data identify the AhR pathway in these mutant mice as crucial for the immunomodulatory, but not neuroprotective, efficacy of laquinimod in EAE.	laquinimod	135-145	aryl-hydrocarbon receptor	Mus musculus	28-31
27704036-9	2016	Treatment of spontaneous EAE with laquinimod was also associated with increases in CD4+CD25hiFoxp3+ and CD4+CD25+IL-10+ regulatory T cells.	laquinimod	34-44	interleukin 10	Mus musculus	113-118
27231712-9	2016	Stimulated primary mouse astrocytes from laquinimod-treated groups show reduced NF-kappaB activation compared to vehicle-treated controls.	laquinimod	41-51	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	80-89
27231712-10	2016	CONCLUSIONS: Our results confirm that laquinimod prevents demyelination in the cuprizone mouse model for multiple sclerosis via downregulation of NF-kappaB activation.	laquinimod	38-48	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	146-155
26603637-3	2015	The aim of the study was to investigate the therapeutic effect of laquinimod on spontaneous colitis in interleukin-10-gene-deficient mice, an animal model of Crohn"s disease.	laquinimod	66-76	interleukin 10	Mus musculus	103-117
26603637-9	2015	Increased expression and correct distribution of tight junction proteins (occludin and ZO-1) were found in Il10(-/-) mice treated with laquinimod.	laquinimod	135-145	occludin	Mus musculus	74-82
26603637-9	2015	Increased expression and correct distribution of tight junction proteins (occludin and ZO-1) were found in Il10(-/-) mice treated with laquinimod.	laquinimod	135-145	tight junction protein 1	Mus musculus	87-91
25064496-7	2015	After 14 days, only laquinimod (5 mg/kg) demonstrated anxiolytic efficacy in the open field test (p < 0.05), with evidence of increased BDNF in response to 5-25 mg/kg in the hippocampus, but not frontal cortex (p < 0.05).	laquinimod	20-30	brain derived neurotrophic factor	Mus musculus	139-143
25064496-8	2015	In conclusion, laquinimod may possess anxiolytic and antidepressant effects, possibly associated with hippocampal BDNF increase, offering promise for MS patients suffering from psychiatric co-morbidity.	laquinimod	15-25	brain derived neurotrophic factor	Homo sapiens	114-118
25356411-8	2014	Laquinimod prevented the decline in activated microglia of miR124a, a microRNA implicated in maintaining microglia quiescence, and reduced the activity of several signaling pathways (Jun-N-terminal kinase, ribosomal S6 kinase, and AKT/protein kinase B) in activated microglia.	laquinimod	0-10	thymoma viral proto-oncogene 1	Mus musculus	231-234
24574228-10	2014	Laquinimod suppressed macrophage-secreted tumor necrosis factor alpha and induced production of interleukin-10 (IL-10).	laquinimod	0-10	tumor necrosis factor	Mus musculus	42-69
24574228-10	2014	Laquinimod suppressed macrophage-secreted tumor necrosis factor alpha and induced production of interleukin-10 (IL-10).	laquinimod	0-10	interleukin 10	Mus musculus	96-110
24574228-10	2014	Laquinimod suppressed macrophage-secreted tumor necrosis factor alpha and induced production of interleukin-10 (IL-10).	laquinimod	0-10	interleukin 10	Mus musculus	112-117
24574228-11	2014	In addition, laquinimod suppressed interferon-gamma and IL-17 production by lymphocytes and down-regulated expression of activation/costimulatory markers on antigen-presenting cells.	laquinimod	13-23	interferon gamma	Mus musculus	35-51
24574228-11	2014	In addition, laquinimod suppressed interferon-gamma and IL-17 production by lymphocytes and down-regulated expression of activation/costimulatory markers on antigen-presenting cells.	laquinimod	13-23	interleukin 17A	Mus musculus	56-61
23232603-9	2013	Furthermore, laquinimod treatment also preserved cannabinoid CB1 receptor sensitivity, normally lost during EAE.	laquinimod	13-23	cannabinoid receptor 1 (brain)	Mus musculus	61-64
24363970-6	2013	RESULTS: Prophylactic and therapeutic treatment with LQ significantly decreased mean clinical disease scores, inhibited Th1 cytokine production, and decreased the CNS inflammatory response.	laquinimod	53-55	negative elongation factor complex member C/D, Th1l	Mus musculus	120-123
22766690-6	2012	LAQ prevented cuprizone-induced demyelination, microglial activation, axonal transections, reactive gliosis and oligodendroglial apoptoses in wild type and Rag-1-deficient mice.	laquinimod	0-3	recombination activating 1	Mus musculus	156-161
23518712-3	2013	In experimental autoimmune encephalomyelitis, the therapeutic administration of laquinimod beginning during the recovery of SJL mice, prevented further relapses as expected and strongly reduced infiltration of CD4+ and CD8+ T cells in the central nervous system.	laquinimod	80-90	CD4 antigen	Mus musculus	210-213
23518712-5	2013	According to the findings on antigen-presenting cells in the murine system, we found a reduced capacity of human monocyte-derived dendritic cells treated with therapeutic concentrations of laquinimod, upon maturation with lipopolysaccharide, to induce CD4+ T cell proliferation and secretion of pro-inflammatory cytokines.	laquinimod	189-199	CD4 molecule	Homo sapiens	252-255
23518712-7	2013	In laquinimod-treated patients with multiple sclerosis we consistently found reduced chemokine and cytokine secretion by conventional CD1c+ dendritic cells upon lipopolysaccharide stimulation.	laquinimod	3-13	CD1c molecule	Homo sapiens	134-138
23518712-8	2013	Similarly to the animal model of relapsing-remitting multiple sclerosis, dendritic cell subsets were altered in patients upon laquinimod treatment, as the number of conventional CD1c+ and plasmacytoid CD303+ dendritic cells were decreased within peripheral blood mononuclear cells.	laquinimod	126-136	CD1c molecule	Homo sapiens	178-182
23518712-9	2013	Moreover, laquinimod treatment in patients with multiple sclerosis and mice modified the maturation of dendritic cells demonstrated by an upregulation of CD86 expression in vivo.	laquinimod	10-20	CD86 antigen	Mus musculus	154-158
22749337-0	2012	Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.	laquinimod	20-30	brain derived neurotrophic factor	Mus musculus	63-96
22749337-5	2012	Laquinimod treatment restored BDNF expression to its level in healthy controls.	laquinimod	0-10	brain derived neurotrophic factor	Mus musculus	30-34
23616636-7	2013	Targeting IL-17 via specific neutralizing antibodies or a small inhibitory molecule, laquinimod, significantly decreased M1/M2 ratio and concomitantly suppressed BRONJ-like condition in mice.	laquinimod	85-95	interleukin 17A	Mus musculus	10-15
16472873-0	2006	Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o.	laquinimod	86-96	interferon beta 1, fibroblast	Mus musculus	113-121
21163185-4	2011	DEVELOPMENT: Laquinimod is a new quinolone-carboxamide that has shown efficacy in various animal models of autoimmune disease, including MS. Laquinimod shows immunomodulatory effects, probably through Th1/Th2 shift, but does not lead to immunosuppression.	laquinimod	13-23	negative elongation factor complex member C/D	Homo sapiens	201-204
21163185-4	2011	DEVELOPMENT: Laquinimod is a new quinolone-carboxamide that has shown efficacy in various animal models of autoimmune disease, including MS. Laquinimod shows immunomodulatory effects, probably through Th1/Th2 shift, but does not lead to immunosuppression.	laquinimod	141-151	negative elongation factor complex member C/D	Homo sapiens	201-204
21163185-5	2011	Laquinimod is metabolised primarily by the CYP3A4 enzyme in the liver.	laquinimod	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
22749771-7	2012	The reduced entry of proinflammatory monocytes into the CNS by laquinimod was attributed to reduction of their levels of CD62L and matrix metalloproteinase-9.	laquinimod	63-73	selectin, lymphocyte	Mus musculus	121-126
22749771-7	2012	The reduced entry of proinflammatory monocytes into the CNS by laquinimod was attributed to reduction of their levels of CD62L and matrix metalloproteinase-9.	laquinimod	63-73	matrix metallopeptidase 9	Mus musculus	131-157
22417253-8	2012	Transient elevations in alanine aminotransferase levels to greater than three times the upper limit of the normal range were observed in 24 patients receiving laquinimod (5%) and 8 receiving placebo (2%).	laquinimod	159-169	glutamic--pyruvic transaminase	Homo sapiens	24-48
22152994-0	2012	Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.	laquinimod	42-52	brain derived neurotrophic factor	Homo sapiens	70-103
22152994-4	2012	To evaluate the potential neuroprotective capacity of laquinimod via modulation of brain-derived neurotrophic factor (BDNF), we analyzed the expression of BDNF in blood samples from 203 MS patients treated with laquinimod.	laquinimod	54-64	brain derived neurotrophic factor	Homo sapiens	83-116
22152994-4	2012	To evaluate the potential neuroprotective capacity of laquinimod via modulation of brain-derived neurotrophic factor (BDNF), we analyzed the expression of BDNF in blood samples from 203 MS patients treated with laquinimod.	laquinimod	54-64	brain derived neurotrophic factor	Homo sapiens	118-122
22152994-6	2012	Treatment with laquinimod resulted in a significant and persistent increase in BDNF serum levels of MS patients when compared to baseline and placebo-treated patients.	laquinimod	15-25	brain derived neurotrophic factor	Homo sapiens	79-83
22479444-3	2012	Oral laquinimod treatment reversed established RR-EAE and was associated with reduced central nervous system (CNS) inflammation, decreased Th1 and Th17 responses, and an increase in regulatory T cells (Treg).	laquinimod	5-15	negative elongation factor complex member C/D	Homo sapiens	139-142
22479444-5	2012	In vivo laquinimod treatment altered subpopulations of myeloid antigen presenting cells (APC) that included a decrease in CD11c(+)CD11b(+)CD4(+) dendritic cells (DC) and an elevation of CD11b(hi)Gr1(hi) monocytes.	laquinimod	8-18	integrin subunit alpha X	Homo sapiens	122-127
22479444-5	2012	In vivo laquinimod treatment altered subpopulations of myeloid antigen presenting cells (APC) that included a decrease in CD11c(+)CD11b(+)CD4(+) dendritic cells (DC) and an elevation of CD11b(hi)Gr1(hi) monocytes.	laquinimod	8-18	integrin subunit alpha M	Homo sapiens	130-135
22479444-5	2012	In vivo laquinimod treatment altered subpopulations of myeloid antigen presenting cells (APC) that included a decrease in CD11c(+)CD11b(+)CD4(+) dendritic cells (DC) and an elevation of CD11b(hi)Gr1(hi) monocytes.	laquinimod	8-18	integrin subunit alpha M	Homo sapiens	186-191
22479444-9	2012	Inhibition of Th1 and Th17 differentiation was observed only when type II monocytes or DC from laquinimod-treated mice were used as APC, regardless of whether myelin-specific T cells were obtained from laquinimod-treated or untreated mice.	laquinimod	95-105	negative elongation factor complex member C/D, Th1l	Mus musculus	14-17
21429524-4	2011	Furthermore, laquinimod minimizes inflammation, demyelination and axonal damage in MOG-induced EAE in mice treated at disease induction and following clinical disease onset.	laquinimod	13-23	myelin oligodendrocyte glycoprotein	Mus musculus	83-86
21429524-6	2011	Additionally, patients treated with laquinimod demonstrate up-regulation of brain-derived neurotrophic factor (BDNF) in the serum.	laquinimod	36-46	brain derived neurotrophic factor	Homo sapiens	76-109
21429524-6	2011	Additionally, patients treated with laquinimod demonstrate up-regulation of brain-derived neurotrophic factor (BDNF) in the serum.	laquinimod	36-46	brain derived neurotrophic factor	Homo sapiens	111-115
20684995-0	2010	Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.	laquinimod	0-10	interleukin 17A	Mus musculus	69-74
16472873-3	2006	The ability of laquinimod to inhibit disease development was investigated in chronic experimental autoimmune encephalomyelitis (chEAE) in IFN-beta k.o.	laquinimod	15-25	interferon beta 1, fibroblast	Mus musculus	138-146
35163694-3	2022	We found that carboxamide derivatives from laquinimod, tasquinimod, and roquinimex can activate AHR signaling at low nanomolar concentrations.	laquinimod	43-53	aryl hydrocarbon receptor	Homo sapiens	96-99
15764719-0	2005	Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator.	laquinimod	74-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-19
15764719-5	2005	Moreover, ketoconazole and troleandomycin, specific inhibitors of CYP3A4 metabolism, demonstrated a significant inhibition of laquinimod metabolism.	laquinimod	126-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72
15764719-7	2005	In vitro interaction studies with CYP3A4 substrates and possible concomitant medication demonstrated that laquinimod inhibits the metabolism of ethinyl estradiol with an IC50 value of about 150 microM, which is high above the plasma level of laquinimod after clinically relevant doses.	laquinimod	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
15764719-9	2005	In conclusion, the present study demonstrates that laquinimod is a low affinity substrate for CYP3A4 in human liver microsomes.	laquinimod	51-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	94-100
15764719-10	2005	The likelihood for in vivo effects of laquinimod on the metabolism of other CYP3A4 substrates is minor.	laquinimod	38-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82
15764719-11	2005	However, inhibitory effects on the metabolism of laquinimod by potent and specific inhibitors of CYP3A4, such as ketoconazole, are anticipated and should be considered in the continued clinical program for laquinimod.	laquinimod	49-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
15764719-11	2005	However, inhibitory effects on the metabolism of laquinimod by potent and specific inhibitors of CYP3A4, such as ketoconazole, are anticipated and should be considered in the continued clinical program for laquinimod.	laquinimod	206-216	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
15465591-0	2004	Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.	laquinimod	0-10	transforming growth factor, beta 1	Rattus norvegicus	156-164
15465591-0	2004	Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.	laquinimod	12-22	transforming growth factor, beta 1	Rattus norvegicus	156-164
32978613-5	2021	The therapeutic efficacy of laquinimod-loaded nanoparticles was evaluated in the well-established IL-10 -/- spontaneous experimental colitis.	laquinimod	28-38	interleukin 10	Homo sapiens	98-103
33408169-0	2021	Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS.	laquinimod	54-64	aryl-hydrocarbon receptor	Mus musculus	0-25
33408169-3	2021	Laquinimod is a drug developed for the treatment of MS known to activate AHR, but the cellular targets of laquinimod are still not completely known.	laquinimod	0-10	aryl-hydrocarbon receptor	Mus musculus	73-76
33408169-5	2021	RESULTS: We found that AHR activation in astrocytes by laquinimod ameliorates EAE, a preclinical model of MS. Genome-wide RNA-seq transcriptional analyses detected anti-inflammatory effects of laquinimod in glial cells during EAE.	laquinimod	55-65	aryl-hydrocarbon receptor	Mus musculus	23-26
33408169-5	2021	RESULTS: We found that AHR activation in astrocytes by laquinimod ameliorates EAE, a preclinical model of MS. Genome-wide RNA-seq transcriptional analyses detected anti-inflammatory effects of laquinimod in glial cells during EAE.	laquinimod	193-203	aryl-hydrocarbon receptor	Mus musculus	23-26
33203651-0	2021	Laquinimod dampens IL-1beta signaling and Th17-polarizing capacity of monocytes in patients with MS.	laquinimod	0-10	interleukin 1 alpha	Homo sapiens	19-27
33218208-3	2020	We show that human iAstrocytes expressed the receptor for the inflammatory mediator IL1 and responded to it via nuclear translocation of NFkappaB, an event that did not occur if cells were treated with Laquinimod, indicating a direct anti-inflammatory activity of the drug on the human astrocyte.	laquinimod	202-212	interleukin 1 alpha	Homo sapiens	84-87
33218208-5	2020	Laquinimod also induced nuclear translocation of the aryl hydrocarbon receptor (AHR), suggesting that drug action was mediated by activation of the AHR pathway.	laquinimod	0-10	aryl hydrocarbon receptor	Homo sapiens	53-78
33218208-5	2020	Laquinimod also induced nuclear translocation of the aryl hydrocarbon receptor (AHR), suggesting that drug action was mediated by activation of the AHR pathway.	laquinimod	0-10	aryl hydrocarbon receptor	Homo sapiens	80-83
33218208-5	2020	Laquinimod also induced nuclear translocation of the aryl hydrocarbon receptor (AHR), suggesting that drug action was mediated by activation of the AHR pathway.	laquinimod	0-10	aryl hydrocarbon receptor	Homo sapiens	148-151
33203651-6	2021	Laquinimod-treated monocytes were cocultured with CD4+ T cells, and the resulting cytokine production was analyzed by flow cytometry after intracellular cytokine staining.	laquinimod	0-10	CD4 molecule	Homo sapiens	50-53
33203651-8	2021	RESULTS: Laquinimod did not alter the frequency or viability of circulating monocytes, but led to an upregulation of CD86 expression.	laquinimod	9-19	CD86 molecule	Homo sapiens	117-121
33203651-9	2021	LPS-stimulated monocytes of laquinimod-treated patients with MS secreted less IL-1beta following a downregulation of IL-1beta gene expression.	laquinimod	28-38	interleukin 1 alpha	Homo sapiens	78-86
33203651-9	2021	LPS-stimulated monocytes of laquinimod-treated patients with MS secreted less IL-1beta following a downregulation of IL-1beta gene expression.	laquinimod	28-38	interleukin 1 alpha	Homo sapiens	117-125
33203651-10	2021	Phosphorylation levels of the NF-kappaB p65 subunit were reduced after laquinimod treatment, indicating a laquinimod-associated inhibition of the NF-kappaB pathway.	laquinimod	71-81	RELA proto-oncogene, NF-kB subunit	Homo sapiens	30-43
33203651-10	2021	Phosphorylation levels of the NF-kappaB p65 subunit were reduced after laquinimod treatment, indicating a laquinimod-associated inhibition of the NF-kappaB pathway.	laquinimod	71-81	nuclear factor kappa B subunit 1	Homo sapiens	30-39
33203651-10	2021	Phosphorylation levels of the NF-kappaB p65 subunit were reduced after laquinimod treatment, indicating a laquinimod-associated inhibition of the NF-kappaB pathway.	laquinimod	106-116	RELA proto-oncogene, NF-kB subunit	Homo sapiens	30-43
33203651-10	2021	Phosphorylation levels of the NF-kappaB p65 subunit were reduced after laquinimod treatment, indicating a laquinimod-associated inhibition of the NF-kappaB pathway.	laquinimod	106-116	nuclear factor kappa B subunit 1	Homo sapiens	30-39
33203651-11	2021	T cells primed with laquinimod-treated monocytes differentiated significantly less into IL-17A-producing T helper (Th)-17 cells.	laquinimod	20-30	interleukin 17A	Homo sapiens	88-94
32237115-0	2020	The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.	laquinimod	72-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-19
33244468-8	2020	Laquinimod significantly downregulated the expression of chemokines (monocyte chemotactic protein-1 and macrophage inflammatory protein-1), pro-inflammatory cytokines (interleukin-1beta and tumor necrosis factor-alpha), vascular endothelial growth factor, nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 and apoptosis-associated speck-like protein containing C-terminal caspase-recruitment domain adaptor protein in both injured corneas and RAW cells.	laquinimod	0-10	C-C motif chemokine ligand 2	Homo sapiens	69-99
33244468-8	2020	Laquinimod significantly downregulated the expression of chemokines (monocyte chemotactic protein-1 and macrophage inflammatory protein-1), pro-inflammatory cytokines (interleukin-1beta and tumor necrosis factor-alpha), vascular endothelial growth factor, nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 and apoptosis-associated speck-like protein containing C-terminal caspase-recruitment domain adaptor protein in both injured corneas and RAW cells.	laquinimod	0-10	interleukin 1 beta	Homo sapiens	168-185
33244468-8	2020	Laquinimod significantly downregulated the expression of chemokines (monocyte chemotactic protein-1 and macrophage inflammatory protein-1), pro-inflammatory cytokines (interleukin-1beta and tumor necrosis factor-alpha), vascular endothelial growth factor, nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 and apoptosis-associated speck-like protein containing C-terminal caspase-recruitment domain adaptor protein in both injured corneas and RAW cells.	laquinimod	0-10	tumor necrosis factor	Homo sapiens	190-217
33244468-8	2020	Laquinimod significantly downregulated the expression of chemokines (monocyte chemotactic protein-1 and macrophage inflammatory protein-1), pro-inflammatory cytokines (interleukin-1beta and tumor necrosis factor-alpha), vascular endothelial growth factor, nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 and apoptosis-associated speck-like protein containing C-terminal caspase-recruitment domain adaptor protein in both injured corneas and RAW cells.	laquinimod	0-10	vascular endothelial growth factor A	Homo sapiens	220-254
32237115-7	2020	Coadministration of laquinimod with CYP3A inhibitors, ketoconazole, fluconazole, and cimetidine increased laquinimod area under the plasma concentration-time curve from time zero to infinity by approximately 3.1-, 2.5-, and 1.1-fold, respectively.	laquinimod	20-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-41
32237115-7	2020	Coadministration of laquinimod with CYP3A inhibitors, ketoconazole, fluconazole, and cimetidine increased laquinimod area under the plasma concentration-time curve from time zero to infinity by approximately 3.1-, 2.5-, and 1.1-fold, respectively.	laquinimod	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-41
32237115-9	2020	These results indicate that coadministration of laquinimod with moderate to strong inhibitors of CYP3A or strong inducers of CYP3A may give rise to significant pharmacokinetic drug interactions.	laquinimod	48-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-102
32237115-1	2020	Laquinimod, a neuroimmunomodulator, is extensively metabolized by cytochrome P450 (CYP) 3A4, and modulations of CYP3A4 activity may lead to alterations in the pharmacokinetics and/or clinical effects of laquinimod.	laquinimod	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-91
32237115-9	2020	These results indicate that coadministration of laquinimod with moderate to strong inhibitors of CYP3A or strong inducers of CYP3A may give rise to significant pharmacokinetic drug interactions.	laquinimod	48-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-130
32237115-1	2020	Laquinimod, a neuroimmunomodulator, is extensively metabolized by cytochrome P450 (CYP) 3A4, and modulations of CYP3A4 activity may lead to alterations in the pharmacokinetics and/or clinical effects of laquinimod.	laquinimod	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
32237115-1	2020	Laquinimod, a neuroimmunomodulator, is extensively metabolized by cytochrome P450 (CYP) 3A4, and modulations of CYP3A4 activity may lead to alterations in the pharmacokinetics and/or clinical effects of laquinimod.	laquinimod	203-213	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
32237115-2	2020	To determine the drug-drug interaction potential of laquinimod with CYP3A inhibitors and inducers, interaction assessments were conducted in healthy volunteers using single-dose administration of laquinimod before and after multiple dosing of CYP3A inhibitors (ketoconazole, fluconazole, and cimetidine) or a CYP3A4 inducer (rifampin).	laquinimod	52-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-73
33182069-8	2020	Importantly, LQ inhibited the expression of cleaved caspase-8 and the downstream NLRP3 inflammasome and IL-1beta.	laquinimod	13-15	caspase 8	Mus musculus	52-61
33182069-8	2020	Importantly, LQ inhibited the expression of cleaved caspase-8 and the downstream NLRP3 inflammasome and IL-1beta.	laquinimod	13-15	NLR family, pyrin domain containing 3	Mus musculus	81-86
33182069-8	2020	Importantly, LQ inhibited the expression of cleaved caspase-8 and the downstream NLRP3 inflammasome and IL-1beta.	laquinimod	13-15	interleukin 1 alpha	Mus musculus	104-112
32249647-0	2020	Laquinimod inhibits MMP+ induced NLRP3 inflammasome activation in human neuronal cells.	laquinimod	0-10	NLR family pyrin domain containing 3	Homo sapiens	33-38
32500758-0	2020	Retraction: Laquinimod inhibits MMP-induced NLRP3 inflammasome activation in human neuronal cells.	laquinimod	12-22	NLR family pyrin domain containing 3	Homo sapiens	44-49
32668270-3	2020	In this study, the anti-estrogenic potential of the AHR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and DELAQ, a metabolite of the pharmaceutical laquinimod, was assessed in in primary human and rat endometrial epithelial cells (EECs) with and without co-exposure to endogenous hormones.	laquinimod	153-163	aryl hydrocarbon receptor	Homo sapiens	52-55
32954145-0	2020	Laquinimod Prevents Adipogenesis and Obesity by Down-Regulating PPAR-gamma and C/EBPalpha through Activating AMPK.	laquinimod	0-10	peroxisome proliferator activated receptor gamma	Mus musculus	64-74
32954145-0	2020	Laquinimod Prevents Adipogenesis and Obesity by Down-Regulating PPAR-gamma and C/EBPalpha through Activating AMPK.	laquinimod	0-10	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	79-89
32954145-7	2020	RESULTS: the amount and UV absorption of oil red O, glycerol production, release of triglyceride, and the expression of SREBP1, FABP4, and Glut4 in differentiated 3T3-L1 cells were decreased by the administration of laquinimod.	laquinimod	216-226	sterol regulatory element binding transcription factor 1	Mus musculus	120-126
32954145-10	2020	CONCLUSION: laquinimod might prevent adipogenesis by down-regulating PPAR-gamma and C/EBPalpha through activating AMPK.	laquinimod	12-22	peroxisome proliferator activated receptor gamma	Mus musculus	69-79
32954145-10	2020	CONCLUSION: laquinimod might prevent adipogenesis by down-regulating PPAR-gamma and C/EBPalpha through activating AMPK.	laquinimod	12-22	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	84-94
32249647-3	2020	This study aims to investigate whether laquinimod possessesa protective effect against MPP+-induced NLRP3 activation.Materials and methods: In a variety of tests on human SH-SY5Y neuronal cells, 1-methyl-4-phenyl Pyridine (MPP+) was used to mimic the microenvironment of PD.	laquinimod	39-49	NLR family pyrin domain containing 3	Homo sapiens	100-105
32249647-6	2020	Importantly, treatment with laquinimod significantly inhibited the activation of the NLRP3 inflammasome by reducing the levels of its components, including NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), and cleaved caspase 1 (P10).	laquinimod	28-38	NLR family pyrin domain containing 3	Homo sapiens	85-90
32249647-6	2020	Importantly, treatment with laquinimod significantly inhibited the activation of the NLRP3 inflammasome by reducing the levels of its components, including NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), and cleaved caspase 1 (P10).	laquinimod	28-38	NLR family pyrin domain containing 3	Homo sapiens	156-161
32249647-6	2020	Importantly, treatment with laquinimod significantly inhibited the activation of the NLRP3 inflammasome by reducing the levels of its components, including NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), and cleaved caspase 1 (P10).	laquinimod	28-38	PYD and CARD domain containing	Homo sapiens	163-220
32249647-6	2020	Importantly, treatment with laquinimod significantly inhibited the activation of the NLRP3 inflammasome by reducing the levels of its components, including NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), and cleaved caspase 1 (P10).	laquinimod	28-38	PYD and CARD domain containing	Homo sapiens	222-225
32249647-6	2020	Importantly, treatment with laquinimod significantly inhibited the activation of the NLRP3 inflammasome by reducing the levels of its components, including NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), and cleaved caspase 1 (P10).	laquinimod	28-38	S100 calcium binding protein A10	Homo sapiens	251-254
32249647-7	2020	Consistently, laquinimod prevented MPP+-induced secretions of interleukin 1beta (IL-1beta) and interleukin-18 (IL-18).	laquinimod	14-24	interleukin 1 beta	Homo sapiens	62-79
32249647-7	2020	Consistently, laquinimod prevented MPP+-induced secretions of interleukin 1beta (IL-1beta) and interleukin-18 (IL-18).	laquinimod	14-24	interleukin 1 alpha	Homo sapiens	81-89
32249647-7	2020	Consistently, laquinimod prevented MPP+-induced secretions of interleukin 1beta (IL-1beta) and interleukin-18 (IL-18).	laquinimod	14-24	interleukin 18	Homo sapiens	95-109
32249647-7	2020	Consistently, laquinimod prevented MPP+-induced secretions of interleukin 1beta (IL-1beta) and interleukin-18 (IL-18).	laquinimod	14-24	interleukin 18	Homo sapiens	111-116
32249647-8	2020	Additionally, laquinimod also reduced the expression of other related factors, such as intracellular reactive oxygen species (ROS), NADPH oxidase 4 (NOX-4), thioredoxin-interacting protein (TxNIP).	laquinimod	14-24	NADPH oxidase 4	Homo sapiens	132-147
32249647-8	2020	Additionally, laquinimod also reduced the expression of other related factors, such as intracellular reactive oxygen species (ROS), NADPH oxidase 4 (NOX-4), thioredoxin-interacting protein (TxNIP).	laquinimod	14-24	NADPH oxidase 4	Homo sapiens	149-154
32249647-8	2020	Additionally, laquinimod also reduced the expression of other related factors, such as intracellular reactive oxygen species (ROS), NADPH oxidase 4 (NOX-4), thioredoxin-interacting protein (TxNIP).	laquinimod	14-24	thioredoxin interacting protein	Homo sapiens	157-188
32249647-8	2020	Additionally, laquinimod also reduced the expression of other related factors, such as intracellular reactive oxygen species (ROS), NADPH oxidase 4 (NOX-4), thioredoxin-interacting protein (TxNIP).	laquinimod	14-24	thioredoxin interacting protein	Homo sapiens	190-195
32249647-9	2020	Furthermore, laquinimod prevented the reduction of sirtuin 1 (SIRT1) from MPP+ stimulation.	laquinimod	13-23	sirtuin 1	Homo sapiens	51-60
32249647-9	2020	Furthermore, laquinimod prevented the reduction of sirtuin 1 (SIRT1) from MPP+ stimulation.	laquinimod	13-23	sirtuin 1	Homo sapiens	62-67
32249647-10	2020	Inhibition of SIRT1 abolished the protective effects of laquinimod against the activation of the NLRP3 inflammasome, suggesting the involvement of SIRT1 in this process.Conclusion: These findings suggest that laquinimod treatment might be a possible therapeutic strategy for neuroinflammation in PD.	laquinimod	56-66	sirtuin 1	Homo sapiens	14-19
32249647-10	2020	Inhibition of SIRT1 abolished the protective effects of laquinimod against the activation of the NLRP3 inflammasome, suggesting the involvement of SIRT1 in this process.Conclusion: These findings suggest that laquinimod treatment might be a possible therapeutic strategy for neuroinflammation in PD.	laquinimod	56-66	NLR family pyrin domain containing 3	Homo sapiens	97-102
32249647-10	2020	Inhibition of SIRT1 abolished the protective effects of laquinimod against the activation of the NLRP3 inflammasome, suggesting the involvement of SIRT1 in this process.Conclusion: These findings suggest that laquinimod treatment might be a possible therapeutic strategy for neuroinflammation in PD.	laquinimod	209-219	sirtuin 1	Homo sapiens	14-19
32249647-10	2020	Inhibition of SIRT1 abolished the protective effects of laquinimod against the activation of the NLRP3 inflammasome, suggesting the involvement of SIRT1 in this process.Conclusion: These findings suggest that laquinimod treatment might be a possible therapeutic strategy for neuroinflammation in PD.	laquinimod	209-219	NLR family pyrin domain containing 3	Homo sapiens	97-102
32249647-10	2020	Inhibition of SIRT1 abolished the protective effects of laquinimod against the activation of the NLRP3 inflammasome, suggesting the involvement of SIRT1 in this process.Conclusion: These findings suggest that laquinimod treatment might be a possible therapeutic strategy for neuroinflammation in PD.	laquinimod	209-219	sirtuin 1	Homo sapiens	147-152
32440094-0	2020	Laquinimod Protects Against TNF-alpha-Induced Attachment of Monocytes to Human Aortic Endothelial Cells (HAECs) by Increasing the Expression of KLF2.	laquinimod	0-10	tumor necrosis factor	Homo sapiens	28-37
32440094-0	2020	Laquinimod Protects Against TNF-alpha-Induced Attachment of Monocytes to Human Aortic Endothelial Cells (HAECs) by Increasing the Expression of KLF2.	laquinimod	0-10	Kruppel like factor 2	Homo sapiens	144-148
32440094-4	2020	In the present study, for the first time, we investigated the effects of laquinimod, an immunomodulatory agent used for the treatment of multiple sclerosis, on human aortic endothelial in a TNF-alpha-induced atherosclerotic microenvironment.	laquinimod	73-83	tumor necrosis factor	Homo sapiens	190-199
32440094-6	2020	Methods: The effects of laquinimod on the gene expression of IL-6, MCP-1, VCAM-1, E-selectin, and KLF2 were measured by real-time PCR.	laquinimod	24-34	interleukin 6	Homo sapiens	61-65
32440094-6	2020	Methods: The effects of laquinimod on the gene expression of IL-6, MCP-1, VCAM-1, E-selectin, and KLF2 were measured by real-time PCR.	laquinimod	24-34	C-C motif chemokine ligand 2	Homo sapiens	67-72
32440094-6	2020	Methods: The effects of laquinimod on the gene expression of IL-6, MCP-1, VCAM-1, E-selectin, and KLF2 were measured by real-time PCR.	laquinimod	24-34	vascular cell adhesion molecule 1	Homo sapiens	74-80
32440094-6	2020	Methods: The effects of laquinimod on the gene expression of IL-6, MCP-1, VCAM-1, E-selectin, and KLF2 were measured by real-time PCR.	laquinimod	24-34	selectin E	Homo sapiens	82-92
32440094-6	2020	Methods: The effects of laquinimod on the gene expression of IL-6, MCP-1, VCAM-1, E-selectin, and KLF2 were measured by real-time PCR.	laquinimod	24-34	Kruppel like factor 2	Homo sapiens	98-102
32440094-10	2020	Results: Our findings demonstrate that laquinimod reduced the expression of key inflammatory cytokines and chemokines, including IL-6, MCP-1, and HMGB1.	laquinimod	39-49	interleukin 6	Homo sapiens	129-133
32440094-10	2020	Results: Our findings demonstrate that laquinimod reduced the expression of key inflammatory cytokines and chemokines, including IL-6, MCP-1, and HMGB1.	laquinimod	39-49	C-C motif chemokine ligand 2	Homo sapiens	135-140
32440094-10	2020	Results: Our findings demonstrate that laquinimod reduced the expression of key inflammatory cytokines and chemokines, including IL-6, MCP-1, and HMGB1.	laquinimod	39-49	high mobility group box 1	Homo sapiens	146-151
32440094-11	2020	We further demonstrate that laquinimod significantly reduced the attachment of monocytes to endothelial cells, which is mediated through reduced expression of the cellular adhesion molecules VCAM-1 and E-selectin.	laquinimod	28-38	vascular cell adhesion molecule 1	Homo sapiens	191-197
32440094-11	2020	We further demonstrate that laquinimod significantly reduced the attachment of monocytes to endothelial cells, which is mediated through reduced expression of the cellular adhesion molecules VCAM-1 and E-selectin.	laquinimod	28-38	selectin E	Homo sapiens	202-212
32440094-12	2020	Here, we found that laquinimod could significantly increase the expression of KLF2 through activation of ERK5 signaling.	laquinimod	20-30	Kruppel like factor 2	Homo sapiens	78-82
32440094-12	2020	Here, we found that laquinimod could significantly increase the expression of KLF2 through activation of ERK5 signaling.	laquinimod	20-30	mitogen-activated protein kinase 7	Homo sapiens	105-109
32440094-13	2020	The results of our KLF2 knockdown experiment confirm that the effects of laquinimod observed in vitro are dependent on KLF2 expression.	laquinimod	73-83	Kruppel like factor 2	Homo sapiens	19-23
32440094-13	2020	The results of our KLF2 knockdown experiment confirm that the effects of laquinimod observed in vitro are dependent on KLF2 expression.	laquinimod	73-83	Kruppel like factor 2	Homo sapiens	119-123
32191437-0	2020	Laquinimod Mitigated IL-1beta-Induced Impairment of the Cartilage Extracellular Matrix in Human ATDC5 Chondrocytes.	laquinimod	0-10	interleukin 1 alpha	Homo sapiens	21-29
32191437-5	2020	In our research, we found that laquinimod could ameliorate IL-1beta-induced generation of ROS and improve mitochondrial function by increasing mitochondrial membrane potential (DeltaPsim).	laquinimod	31-41	interleukin 1 alpha	Homo sapiens	59-67
32191437-6	2020	Furthermore, treatment with laquinimod suppressed IL-1beta-induced production of TNF-alpha and IL-6.	laquinimod	28-38	interleukin 1 alpha	Homo sapiens	50-58
32191437-6	2020	Furthermore, treatment with laquinimod suppressed IL-1beta-induced production of TNF-alpha and IL-6.	laquinimod	28-38	tumor necrosis factor	Homo sapiens	81-90
32191437-6	2020	Furthermore, treatment with laquinimod suppressed IL-1beta-induced production of TNF-alpha and IL-6.	laquinimod	28-38	interleukin 6	Homo sapiens	95-99
32191437-7	2020	Notably, laquinimod prevented the degradation of type II collagen by inhibiting MMP-3 and MMP-13.	laquinimod	9-19	matrix metallopeptidase 3	Homo sapiens	80-85
32191437-7	2020	Notably, laquinimod prevented the degradation of type II collagen by inhibiting MMP-3 and MMP-13.	laquinimod	9-19	matrix metallopeptidase 13	Homo sapiens	90-96
32191437-8	2020	Meanwhile, the presence of laquinimod attenuated the reduction in aggrecan by mediating ADAMTS-4 and ADAMTS-5.	laquinimod	27-37	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	88-96
32191437-8	2020	Meanwhile, the presence of laquinimod attenuated the reduction in aggrecan by mediating ADAMTS-4 and ADAMTS-5.	laquinimod	27-37	ADAM metallopeptidase with thrombospondin type 1 motif 5	Homo sapiens	101-109
32191437-9	2020	Mechanistically, laquinimod ameliorated IL-1beta-induced inflammation and degeneration of ECM by suppressing the activation of NF-kappaB.	laquinimod	17-27	interleukin 1 alpha	Homo sapiens	40-48
32191437-9	2020	Mechanistically, laquinimod ameliorated IL-1beta-induced inflammation and degeneration of ECM by suppressing the activation of NF-kappaB.	laquinimod	17-27	nuclear factor kappa B subunit 1	Homo sapiens	127-136
32191437-10	2020	Taken together, our findings reveal that laquinimod possesses a beneficial effect against IL-1beta insults in human chondrocytes, implying an important role of laquinimod in OA.	laquinimod	41-51	interleukin 1 alpha	Homo sapiens	90-98
30334188-5	2019	In addition, we demonstrated for the first time the beneficial effects of laquinimod on myelination in the posterior region of the CC where it reversed changes in myelin sheath thickness and rescued Mbp mRNA and protein deficits.	laquinimod	74-84	myelin basic protein	Mus musculus	199-202
30334188-6	2019	Furthermore, the effect of laquinimod on myelin-related gene expression was not region-specific since the levels of the Mbp and Plp1 transcripts were also increased in the striatum.	laquinimod	27-37	myelin basic protein	Mus musculus	120-123
30334188-6	2019	Furthermore, the effect of laquinimod on myelin-related gene expression was not region-specific since the levels of the Mbp and Plp1 transcripts were also increased in the striatum.	laquinimod	27-37	proteolipid protein (myelin) 1	Mus musculus	128-132
30893768-4	2019	Clinical trials on LAQ have not reported any significant toxic outcomes and C2 has shown low toxicity in rats; however, their functional resemblance to the highly toxic AHR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) raises questions.	laquinimod	19-22	aryl hydrocarbon receptor	Rattus norvegicus	169-172
30808363-0	2019	Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.	laquinimod	0-10	aryl hydrocarbon receptor	Homo sapiens	53-78
30808363-0	2019	Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.	laquinimod	0-10	PVR cell adhesion molecule	Homo sapiens	99-104
30808363-7	2019	RESULTS: We demonstrate that laquinimod activates natural killer (NK) cells via the aryl hydrocarbon receptor and increases their DNAM-1 cell surface expression.	laquinimod	29-39	aryl hydrocarbon receptor	Homo sapiens	84-109
30808363-7	2019	RESULTS: We demonstrate that laquinimod activates natural killer (NK) cells via the aryl hydrocarbon receptor and increases their DNAM-1 cell surface expression.	laquinimod	29-39	CD226 molecule	Homo sapiens	130-136